VCNX - Versatile Vaccinex Needs A Trial Or Partner Win But Scaled Down Operation May Be More Likely
Investment Thesis
Vaccinex share price performance since IPO. Source: TradingView.
A review of Vaccinex's (VCNX) recent share price performance and funding runway might persuade investors to leave this early stage biotech stock well alone, but there is also a case to be made that the stock represents a risky potential buying opportunity ahead of some make-or-break trial results.
Vaccinex's lead candidate, Pepinemab - an inhibitor of semaphorin 4D ("SEMA4D") is a unique and potentially effective treatment not only for neurodegenerative diseases, but also for oncological indications.
So far, the treatment has failed